Targeting precision medicine toxicity: Recent developments

Therapeutic Advances in Drug Safety

Volumn 6, Issue 1, 2015, Pages 4-14

  Mallarkey, Gordon ^a   Mangoni, Arduino A ^b  

^a SAGE Publications Ltd   (United Kingdom)

^b FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; B RAF KINASE; BILE ACID; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR;

BILE ACID MALABSORPTION; BILE ACID METABOLISM; CARDIOTOXICITY; DIARRHEA; DRUG SAFETY; EDITORIAL; ENDOCRINE DISEASE; ENDOCRINE TOXICITY; GASTROINTESTINAL TOXICITY; HUMAN; HYPOPHYSITIS; HYPOPITUITARISM; HYPOTHYROIDISM; LUNG TOXICITY; MALABSORPTION; MEDICAL SOCIETY; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SECONDARY HYPERPARATHYROIDISM; SKIN TOXICITY;

EID: 84939214546     PISSN: 20420986     EISSN: 20420994     Source Type: Journal    
DOI: 10.1177/2042098614560737     Document Type: Editorial

References (40)

1. Andreyev H. Davidson S. Gillespie C. Allum W. Swarbrick E. British Society of Gastroenterology. (2012) Practice guidance on the management of acute and chronic gastrointestinal problems arising as a result of treatment for cancer. Gut 61: 179–192.
2. Andreyev J. Ross P. Donnellan C. Lennan E. Leonard P. Waters C. (2014) Guidance on the management of diarrhoea during cancer chemotherapy. Lancet Oncol 15: e447–e460.
3. Anker C. Ribas A. Grossmann A. Chen X. Narra K. Akerley W. (2013) Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma. J Clin Oncol 31: e283–e287.
4. Brahmer J. Drake C. Wollner I. Powderly J. Picus J. Sharfman W. (2010) Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28: 3167–3175.
5. Brahmer J. Pardoll D. (2013) Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer. Cancer Immunol Res 1: 85–91.
6. Brahmer J. Tykodi S. Chow L. Hwu W. Topalian S. Hwu P. (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366: 2455–2465.
7. Camacho L. Antonia S. Sosman J. Kirkwood J. Gajewski T. Redman B. (2009) Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol 27: 1075–1081.
8. Chapman P. Hauschild A. Robert C. Haanen J. Ascierto P. Larkin J. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507–2516.
9. Chau I. Norman A. Cunningham D. Tait D. Ross P. Iveson T. (2005) A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol 16: 549–557.
10. Curigliano G. Cardinale D Suter T Plataniotis G de Azambuja E Sandri M. (2012) Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol 23(Suppl. 7): vii155–vii166.
11. Faje A. Sullivan R. Lawrence D. Tritos N. Fadden R. Klibanski A. (2014) Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab. 31 July 2014. jc20142306. [Epub ahead of print].
12. Falcone A. Ricci S. Brunetti I. Pfanner E. Allegrini G. Barbara C. (2007) Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25: 1670–1676.
13. Flaherty K. Infante J. Daud A. Gonzalez R. Kefford R. Sosman J. (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367: 1694–1703.
14. Force T. Krause D. van Etten R. (2007) Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 7: 332–344.
15. Fuchs C. Marshall J. Mitchell E. Wierzbicki R. Ganju V. Jeffery M. (2007) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 25: 4779–4786.
16. Gartrell B. Ying J. Sivendran S. Boucher K. Choueiri T. Sonpavde G. (2014) Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis. Target Oncol 9: 195–204.
17. Gillespie C. Goode C. Hackett C. Andreyev H. (2007) The clinical needs of patients with chronic gastrointestinal symptoms after pelvic radiotherapy. Aliment Pharmacol Ther 26: 555–563.
18. Grace E. Shaw C. Whelan K. Andreyev H. (2013) Review article: small intestinal bacterial overgrowth–prevalence, clinical features, current and developing diagnostic tests, and treatment. Aliment Pharmacol Ther 38: 674–688.
19. Hamid O. Robert C. Daud A. Hodi F. Hwu W. Kefford R. (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369: 134–144.
20. Hauschild A Grob J Demidov L Jouary T Gutzmer R Millward M. (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380: 358–365.
21. Kudoh S. Kato H. Nishiwaki Y. Fukuoka M. Nakata K. Ichinose Y. (2008) Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med 177: 1348–1357.
22. Montani D. Bergot E. Günther S. Savale L. Bergeron A. Bourdin A. (2012) Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 125: 2128–2137.
23. Morris V Kopetz S. (2013) BRAF inhibitors in clinical oncology. F1000Prime Reports. DOI: 10.12703/P5-11.
24. O–Shaughnessy J. Miles D. Vukelja S. Moiseyenko V. Ayoub J. Cervantes G. (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20: 2812–2823.
25. Osio A. Mateus C. Soria J. Massard C. Malka D. Boige V. (2009) Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors. Br J Dermatol 161: 515–521.
26. Pawlyn C. Khan M. Muls A. Sriskandarajah P. Kaiser M. Davies F. (2014) Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment. Blood 124: 2467–2468.
27. Ribas A. Camacho L. Lopez-Berestein G. Pavlov D. Bulanhagui C. Millham R. (2005) Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 23: 8968–8977.
28. Sakai F. Johkoh T. Kusumoto M. Arakawa H. Takahashi M. (2012) Drug-induced interstitial lung disease in molecular targeted therapies: high-resolution CT findings. Int J Clin Oncol 17: 542–550.
29. Saltz L. Douillard J. Pirotta N. Alakl M. Gruia G. Awad L. (2001) Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard. Oncologist 6: 81–91.
30. Sargis R. Salgia R. (2013) Multiple endocrine disruption by the MET/ALK inhibitor crizotinib in patients with non-small cell lung cancer. Am J Clin Oncol. 7 August 2013. [Epub ahead of print].
31. Small H. Montezano A. Rios F. Savoia C. Touyz R. (2014) Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome. Can J Cardiol 30: 534–543.
32. Strevel E. Ing D. Siu L. (2007) Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol 25: 3362–3371.
33. Tanaka C. Yin O. Sethuraman V. Smith T. Wang X. Grouss K. (2010) Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib. Clin Pharmacol Ther 87: 197–203.
34. Toffalorio F. Spitaleri G. Catania C. Dal Zotto L. Noberasco C. Delmonte A. (2014) Phase Ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets. Oncologist 19: 344–345.
35. Togashi Y. Masago K. Hamatani Y. Sakamori Y. Nagai H. Kim Y. (2012) Mishima M. Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: a case report and review of the literature. Lung Cancer 77: 464–468.
36. Topalian S. Hodi F. Brahmer J. Gettinger S. Smith D. McDermott D. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443–2454.
37. Tveit KM. Guren T. Glimelius B. Pfeiffer P. Sorbye H. Pyrhonen S. (2012) Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol 30: 1755–62.
38. Van Cutsem E. Köhne CH. Láng I. Folprecht G. Nowacki MP. Cascinu S. (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 29: 2011–9.
39. Weber J. O–Day S. Urba W. Powderly J. Nichol G. Yellin M. (2008) Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol 26: 5950–5956.
40. Wedlake L. Thomas K. Lalji A. Anagnostopoulos C. Andreyev H. (2009) Effectiveness and tolerability of colesevelam hydrochloride for bile-acid malabsorption in patients with cancer: a retrospective chart review and patient questionnaire. Clin Ther 31: 2549–2558.